1. Home
  2. UBXG vs OTLK Comparison

UBXG vs OTLK Comparison

Compare UBXG & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBXG
  • OTLK
  • Stock Information
  • Founded
  • UBXG 2018
  • OTLK 2010
  • Country
  • UBXG China
  • OTLK United States
  • Employees
  • UBXG N/A
  • OTLK N/A
  • Industry
  • UBXG
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UBXG
  • OTLK Health Care
  • Exchange
  • UBXG Nasdaq
  • OTLK Nasdaq
  • Market Cap
  • UBXG 60.1M
  • OTLK 48.3M
  • IPO Year
  • UBXG 2024
  • OTLK 2016
  • Fundamental
  • Price
  • UBXG $2.00
  • OTLK $1.04
  • Analyst Decision
  • UBXG
  • OTLK Buy
  • Analyst Count
  • UBXG 0
  • OTLK 5
  • Target Price
  • UBXG N/A
  • OTLK $8.50
  • AVG Volume (30 Days)
  • UBXG 597.6K
  • OTLK 8.0M
  • Earning Date
  • UBXG 01-01-0001
  • OTLK 08-14-2025
  • Dividend Yield
  • UBXG N/A
  • OTLK N/A
  • EPS Growth
  • UBXG N/A
  • OTLK N/A
  • EPS
  • UBXG N/A
  • OTLK N/A
  • Revenue
  • UBXG $39,603,353.00
  • OTLK $1,505,322.00
  • Revenue This Year
  • UBXG N/A
  • OTLK N/A
  • Revenue Next Year
  • UBXG N/A
  • OTLK $484.88
  • P/E Ratio
  • UBXG N/A
  • OTLK N/A
  • Revenue Growth
  • UBXG N/A
  • OTLK N/A
  • 52 Week Low
  • UBXG $1.84
  • OTLK $0.79
  • 52 Week High
  • UBXG $13.60
  • OTLK $6.98
  • Technical
  • Relative Strength Index (RSI)
  • UBXG 33.04
  • OTLK 36.23
  • Support Level
  • UBXG $1.84
  • OTLK $1.02
  • Resistance Level
  • UBXG $2.96
  • OTLK $1.19
  • Average True Range (ATR)
  • UBXG 0.30
  • OTLK 0.11
  • MACD
  • UBXG -0.09
  • OTLK 0.00
  • Stochastic Oscillator
  • UBXG 12.69
  • OTLK 54.29

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: